Decoding MYB: How This Gene Impacts Cancer and Cell Growth
"Uncover the crucial role of the MYB gene in cell development, cancer, and potential therapeutic interventions."
The MYB gene, a key player in cellular processes, was initially identified as the cellular counterpart to the v-myb oncogene found in avian retroviruses. These viruses, known as Avian Myeloblastosis Virus (AMV) and E26, can induce leukemia in chickens, highlighting MYB's significant role in blood cell development and cancer.
Located on the long arm of chromosome 6, the MYB gene spans 37.85 kb and is transcribed from the centromere to the telomere. This gene encodes a protein crucial for the regulation of gene expression, influencing cell proliferation, differentiation, and survival. Understanding MYB's function is vital for unraveling the complexities of cancer development and potential therapeutic interventions.
This article delves into the multifaceted roles of the MYB gene, examining its structure, function, and implications in various cancers. We will explore how MYB's dysregulation contributes to cancer development and how targeting MYB could offer new avenues for cancer treatment. This comprehensive overview aims to provide clear insights into MYB's significance for researchers, healthcare professionals, and anyone keen on understanding the genetic basis of cancer.
MYB Activity in Cancer
MYB encodes a protein with three helix-turn-helix DNA-binding domains that functions as a transcription regulator, according to the NIH Genetic Testing Registry. In the breast cancer cell line MCF-7, the Ness team found that c-MYB bound to more than 10,000 promoters. The study also validated known MYB target genes involved in the cell cycle, including MYC and CCNB1.
Silencing MYB Expression
Reviews of MYB alterations describe approaches aimed at reducing oncogenic transcription-factor activity and addressing tumor-cell plasticity and therapy resistance. One strategy recruits transcriptional repressors to B-MYB loci to silence gene expression without permanent genetic modification. Another uses CRISPR interference, or CRISPRi, in which dCas9 is fused to transcriptional repressor domains for sequence-specific gene silencing. Earlier colorectal cancer cell-line studies also reported robust MYB mRNA expression accompanying MYB gene amplification in a pair of metastatic-cancer-derived lines.
MYB in Development and Disease
MYB has been described as a master regulator of hematopoietic-system development and function. The ScienceDirect overview reports that deregulated MYB expression is associated with hematological and non-hematological malignancies. It also highlights translocations involving MYB in leukemias and other tumor types.
The Structure and Function of MYB: What Makes It Tick?
The MYB protein consists of three key domains, each with a distinct function. The N-terminal helix-turn-helix (HTH) domain, also known as the DNA-binding domain (DBD), enables MYB to attach to specific DNA sequences and regulate gene expression. The centrally located trans-activation domain (TAD) boosts the transcription of target genes, while the C-terminal negative regulatory domain (NRD) controls MYB's activity, preventing it from becoming overactive.
- DNA Binding Domain (DBD): Allows MYB to attach to specific DNA sequences, controlling gene expression.
- Trans-Activation Domain (TAD): Boosts the transcription of target genes, enhancing cell growth and function.
- Negative Regulatory Domain (NRD): Prevents MYB from becoming overactive, maintaining cellular equilibrium.
A Continuing Review of MYB
Zhao, Pattabiraman, and Gonda published a 2011 review of MYB, identified as the v-myb myeloblastosis viral oncogene homolog in avian systems. The work appeared in the Atlas of Genetics and Cytogenetics in Oncology and Haematology. Its focus places MYB within the genetics and cytogenetics literature on oncology and hematology.
Expression Depends on the Test
A 2024 study concluded that immunohistochemical detection of MYB varies significantly according to the antibody used. Comparison with MYB fusions and transcription levels measured by next-generation sequencing showed a complex relationship between genetic alterations, transcript levels, and protein abundance. In adenoid cystic carcinoma, MYB TSS2 activity was significantly higher in metastases than in primary tumors, with median activity of 15.1 versus 3.0 and P = 0.0003. High-TSS2 metastases had increased multidrug-resistance and canonical MYB-target gene expression, alongside suppression of the p53 and NOTCH pathways.
MYB's Role in Cancer: From Leukemia to Solid Tumors
MYB is highly expressed in almost all leukemias, with overexpression also detected in solid tumors such as breast and colon cancer. In T-cell acute lymphoblastic leukemia, translocations involving MYB and the T-cell receptor beta (TCRbeta) locus have been identified, highlighting MYB's direct involvement in cancer development. These genetic alterations disrupt normal MYB regulation, leading to uncontrolled cell proliferation and oncogenesis.
MYB-Targeted Drugs Move Forward
As of 2025, Rgenta and Remix’s MYB-targeted drugs were reported to be approaching an optimal dose for potential future clinical trials. The same report said that both programs were beginning to present encouraging clinical data. It described these drugs as potentially expanding treatment options and targeting a main genetic driver of adenoid cystic carcinoma.
Targeting a Central Transcriptional Regulator
A 2021 review examined links between MYB-family activity and human malignancies, as well as experimental therapeutic interventions tailored to MYB-expressing cancers. A 2024 review describes MYB as a pivotal component of the cellular transcriptional network that influences proliferation, differentiation, and apoptosis. Because of its role in oncogenesis, the review identifies MYB as a compelling therapeutic target and summarizes current approaches intended to inhibit it.
In acute myeloid leukemia (AML), MYB is over-expressed in most cases, making it a critical target for therapeutic intervention. Studies using antisense oligonucleotides and dominant negative forms of MYB have demonstrated that MYB activity is essential for the continued proliferation of AML and CML cells. Furthermore, AML and CML cells are more sensitive to inhibition of MYB than their normal counterparts, suggesting a therapeutic window for targeted MYB inhibition.
The MYB gene is a crucial regulator of cell development and a key player in various cancers. Understanding its structure, function, and implications in disease is essential for developing targeted therapies. By unraveling the complexities of MYB, researchers and healthcare professionals can pave the way for more effective cancer treatments and improved patient outcomes. Future research should focus on developing specific MYB inhibitors and exploring their potential in combination therapies to combat cancer more effectively.